Breast cancer biomarker (HER2-ECD) detection using a molecularly imprinted electrochemical sensor

Abstract The extracellular domain of the human epidermal growth factor receptor 2 (HER2-ECD) is a protein breast cancer biomarker. Its quantification in peripheral blood could provide an important contribution to diagnostics and patient follow-up. In this work an electrochemical molecularly imprinted polymer (MIP) sensor for the quantification of HER2-ECD was developed. The MIP was electropolymerized by cyclic voltammetry using a solution containing phenol and HER2-ECD on a screen-printed gold electrode (AuSPE). The sensor was characterized by cyclic voltammetry and electrochemical impedance spectroscopy. The analysis of HER2-ECD was performed by differential pulse voltammetry using ([Fe(CN)6]3−/4−as redox probe. The linear range was established in the concentration interval from 10 to 70 ng/mL HER2-ECD, with a limit of detection of 1.6 ng/L and a limit of quantification of 5.2 ng/mL. Through the analysis of other protein biomarkers, the MIP sensor was found to be selective. Furthermore, these proteins did not interfere in the analysis of the selected biomarker. The developed sensor was used for the analysis of spiked human serum samples, providing adequate recovery values and precise results. The outcomes of this study indicate that the developed MIP sensor could be useful in the non-invasive analysis of HER2-ECD in breast cancer patients.

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  S. Hanash,et al.  Application of proteomics to cancer early detection. , 2011, Cancer journal.

[3]  F. Stracci.  Cancer screenings, diagnostic technology evolution, and cancer control. , 2009, Methods in molecular biology.

[4]  Fatma Yilmaz,et al.  Molecular Imprinting of Macromolecules for Sensor Applications , 2017, Sensors.

[5]  Xiaqing Wu,et al.  Molecular imprinting: perspectives and applications. , 2016, Chemical Society reviews.

[6]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[7]  Mahdi Emami,et al.  An electrochemical immunosensor for detection of a breast cancer biomarker based on antiHER2-iron oxide nanoparticle bioconjugates. , 2014, The Analyst.

[8]  Cristina Delerue-Matos,et al.  Molecularly imprinted electrochemical sensor prepared on a screen printed carbon electrode for naloxone detection , 2017 .

[9]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[10]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Shamsipur,et al.  A novel antibody-antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode. , 2015, Analytica chimica acta.

[12]  John Gohring,et al.  Detection of HER2 breast cancer biomarker using the opto-fluidic ring resonator biosensor , 2010 .

[13]  Mohammad Hasanzadeh,et al.  Early stage screening of breast cancer using electrochemical biomarker detection , 2017 .

[14]  D G Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2013, British Journal of Cancer.

[15]  C. Delerue-Matos,et al.  Electrochemical immunosensor for the analysis of the breast cancer biomarker HER2 ECD. , 2014, Talanta.

[16]  F. Schmitt,et al.  Molecular Pathology: A Practical Guide for the Surgical Pathologist and Cytopathologist , 2015 .

[17]  Cristina Delerue-Matos,et al.  Molecularly imprinted electrochemical sensor for the point-of-care detection of a breast cancer biomarker (CA 15-3) , 2018 .

[18]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Giovanna Marrazza,et al.  MIP-Based Sensors: Promising New Tools for Cancer Biomarker Determination , 2017, Sensors.

[20]  James Noble,et al.  The rational development of molecularly imprinted polymer-based sensors for protein detection. , 2011, Chemical Society reviews.

[21]  Frieder W. Scheller,et al.  Electrosynthesized molecularly imprinted polymers for protein recognition , 2016 .

[22]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[23]  D. Berry,et al.  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Lamy,et al.  HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. , 2012, Cancer treatment reviews.

[25]  Sunil Mittal,et al.  Biosensors for breast cancer diagnosis: A review of bioreceptors, biotransducers and signal amplification strategies. , 2017, Biosensors & bioelectronics.

[26]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[27]  T. Fehm,et al.  Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients , 2016, BMC Cancer.

[28]  L. Ottini,et al.  HER2-positive male breast cancer: an update. , 2010, Breast cancer.

[29]  F. Montemurro,et al.  Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. , 2013 .

[30]  Hongtao Zhang,et al.  Challenges in the clinical utility of the serum test for HER2 ECD. , 2012, Biochimica et biophysica acta.

[31]  Bhawana Singh,et al.  Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer , 2016, The Indian journal of medical research.

[32]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[33]  R. Kamal,et al.  Breast imaging in the young: the role of magnetic resonance imaging in breast cancer screening, diagnosis and follow-up. , 2013, Journal of thoracic disease.

[34]  Abdollah Noorbakhsh,et al.  Reduced graphene oxide-chitosan-aptamer interface as new platform for ultrasensitive detection of human epidermal growth factor receptor 2. , 2017, Biosensors & bioelectronics.

[35]  V. Heinemann,et al.  Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[36]  Hendrik Koffijberg,et al.  Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility , 2017, International journal of molecular sciences.